NCT07553832

Brief Summary

The pathogenesis of keratoconus remains unclear, and its natural course has yet to be fully understood. For non-progressive patients and post-surgical cases, clinical management primarily involves follow-up observation, with significant challenges in visual rehabilitation. This study aims to establish a prospective keratoconus cohort to identify risk factors, natural progression, and the efficacy of interventions. Additionally, it seeks to explore changes in ocular biometric parameters and other pathophysiological characteristics in keratoconus patients, investigate the relationship between keratoconus and systemic diseases or comorbidities, and assess refractive interventions and visual rehabilitation strategies for keratoconus patients.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
421

participants targeted

Target at P75+ for all trials

Timeline
40mo left

Started Sep 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 14, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 28, 2026

Completed
4 months until next milestone

Study Start

First participant enrolled

September 1, 2026

Expected
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2026

3.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

April 28, 2026

Status Verified

April 1, 2026

Enrollment Period

Same day

First QC Date

April 14, 2026

Last Update Submit

April 20, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Kmax

    Corneal Topography Pentacam

    Baseline, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

Secondary Outcomes (2)

  • BCVA

    Baseline, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

  • BAD-D

    Baseline, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years

Other Outcomes (5)

  • Corneal Endothelial Cell Count

    Baseline, 1 year, 2 years, 3 years, 4 years, 5 years

  • Ocular Biometry Parameters

    Baseline, 1 year, 2 years, 3 years, 4 years, 5 years

  • OCT Imaging Findings

    Baseline, 1 year, 2 years, 3 years, 4 years, 5 years

  • +2 more other outcomes

Study Arms (1)

keratoconus

keratoconus patient

Eligibility Criteria

Age4 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

subclinical keratoconus and keratoconus

You may qualify if:

  • ≤BAD-D \< 2.6 in Pantacam. 1.2 Patients aged 4 years or older. 1.3 informed consent was obtained from patients. If the patient was younger than 18 years of age, the patient and guardian provided written informed consent.
  • The contralateral eye was diagnosed with keratoconus, and the included eye met the following criteria: 2.1.1 BCVA≥1.0 2.1.2 No obvious abnormal signs under slit lamp; 2.1.3 BAD-D \< 2.6 in Pantacam. 2.2 Age ≥ 4 years old. 2.3 informed consent was obtained from patients. If the patient was younger than 18 years of age, the patient and guardian provided written informed consent.
  • History of myopia and astigmatism, BCVA≤1.0 3.2 Slit-lamp examination reveals at least one sign: corneal thinning, conical protrusion, Vogts striae, Fleischers rings, or anterior stromal scarring.
  • abnormal corneal topography features, such as asymmetric bow tie, subtemporal steeping, abnormal thickness distribution, and reduced minimum thickness, with BAD-D≥2.6 in Pantacam.
  • Age ≥ 4 years old. 3.5 Informed consent was obtained from patients. If the patient was younger than 18 years of age, the patient and guardian provided written informed consent.

You may not qualify if:

  • Patients with a history of ocular surgery and significant corneal scarring.
  • Patients who could not understand or cooperate with the examination and follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan Ophthalmic Center Sun Yat-Sen University

Guangzhou, Guangdong, 510060, China

Location

MeSH Terms

Conditions

Keratoconus

Condition Hierarchy (Ancestors)

Corneal DiseasesEye Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2026

First Posted

April 28, 2026

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

December 1, 2029

Last Updated

April 28, 2026

Record last verified: 2026-04

Locations